Scarica l'app Stockscreener
9.67
6.39%
-0.66
Dopo l'orario di chiusura:
9.67
Precedente Chiudi:
$10.33
Aprire:
$10.49
Volume 24 ore:
88,635
Relative Volume:
1.51
Capitalizzazione di mercato:
$90.84M
Reddito:
-
Utile/perdita netta:
$-129.41M
Rapporto P/E:
-0.4014
EPS:
-24.0922
Flusso di cassa netto:
$-51.97M
1 W Prestazione:
-4.16%
1M Prestazione:
+16.09%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$9.56
$10.49
Intervallo di 1 settimana:
$9.17
$11.44
Portata 52W:
$4.21
$14.21
Leonabio Inc Stock (LONA) Company Profile
Nome
Leonabio Inc
Settore
Industria
Telefono
(425) 620-8501
Indirizzo
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare LONA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LONA
Leonabio Inc
|
9.67 | 97.03M | 0 | -129.41M | -51.97M | -24.09 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Leonabio Inc Stock (LONA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-02-19 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-09-19 | Downgrade | Mizuho | Outperform → Neutral |
| 2024-09-04 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-09-04 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | Iniziato | Rodman & Renshaw | Buy |
| 2022-10-17 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-06-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | Downgrade | Jefferies | Buy → Hold |
| 2022-06-23 | Downgrade | Stifel | Buy → Hold |
| 2022-05-10 | Iniziato | BTIG Research | Buy |
| 2022-04-21 | Iniziato | Berenberg | Buy |
| 2021-12-15 | Iniziato | Goldman | Neutral |
| 2020-10-13 | Iniziato | Goldman | Buy |
| 2020-10-13 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-10-13 | Iniziato | Jefferies | Buy |
| 2020-10-13 | Iniziato | Stifel | Buy |
Mostra tutto
Leonabio Inc Borsa (LONA) Ultime notizie
LeonaBio Inc. (LONA) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ReactionDebt Analysis Report - Newser
LeonaBio Inc. (LONA) Q1 2026 Earnings: Narrower-Than-Expected Loss Buoyed by R&D ProgressCrowd Stock Picks - Newser
LeonaBio Inc. (LONA) Q1 2026 Earnings: Narrowing Losses Signal Operational DisciplineRetail Earnings Report - Newser
Why Is LeonaBio, Inc. (LONA) Stock Up Today? - Meyka
Why Is LeonaBio, Inc. (LONA) Stock Down Today? - Meyka
ADAR1, Daniel Schneeberger disclose 727,481 shares in LeonaBio (ATHA) - Stock Titan
LeonaBio (ATHA) details 2026 director, auditor and Say-on-Pay votes - Stock Titan
Mizuho Securities Maintains LeonaBio(LONA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Dividend HistoryLeonaBio, Inc. (LONA) - Zacks Investment Research
LONA: LeonaBio, Inc.Insider Transations - Zacks Investment Research
MSN Money - MSN
LeonaBio (LONA) director receives 56,000 stock options at $9.63 strike - Stock Titan
Director at LeonaBio (LONA) granted 56,000 stock options - Stock Titan
Option grant gives LeonaBio (LONA) director 56,000 shares at $9.63 - Stock Titan
Natalie Holles named LeonaBio (LONA) director in initial Form 3 - Stock Titan
LeonaBio (LONA) director Peter B. Silverman files initial Form 3 - Stock Titan
LeonaBio (LONA) director Callori Fred files baseline Form 3 ownership report - Stock Titan
Perceptive Advisors (ATHA) caps LeonaBio stake at 19.99% and gains board seat - Stock Titan
LeonaBio (NASDAQ: ATHA) widens loss as R&D ramps for lasofoxifene and ALS drug - Stock Titan
LeonaBio (NASDAQ: ATHA) widens Q1 loss while funding late-stage trials - Stock Titan
LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
LeonaBio reshapes board with 3 hires as long-serving director exits - Stock Titan
LeonaBio John Fluke Retires, Effective May 4 >LONA - Moomoo
LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D. - Weekly Voice
LeonaBio Enhances Board of Directors with Appointments of - GlobeNewswire
LeonaBio, Inc. (LONA) Stock Forecast 2027, 2031 & 7-Year Price Prediction | Meyka AI - Meyka
How sustainable is LeonaBio (LONA) profit margins? (Selling Pressure) 2026-05-06Hot Market Picks - newser.com
LONA Earnings History & Surprises | EPS & Revenue Results | LEONABIO INC (NASDAQ:LONA) - ChartMill
LONA LeonaBio reports sharply worse than expected Q4 2025 EPS, shares drop 3.36% on investor disappointment.Sector Underperform - newser.com
Athira Pharma (LONA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $LONA - MarketBeat
LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer - Yahoo Finance
LeonaBio to Host Virtual Key Opinion Leader Event - GlobeNewswire
LeonaBio (LONA) Showcases Lasofoxifene Research at AACR26 - GuruFocus
Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data - The Manila Times
Independent Nonclinical Research on Lasofoxifene Presented - GlobeNewswire
LeonaBio (LONA) Stock: Is It Testing Levels (Overhead Buying) 2026-04-20Earnings Miss Stocks - Xã Thanh Hà
28,000-share stock option grant to LeonaBio (LONA) director - Stock Titan
LeonaBio (LONA) awards 300,000 stock options to chief scientific officer - Stock Titan
28,000 stock options granted to LeonaBio (LONA) director Kosacz - Stock Titan
LeonaBio (LONA) director Grant Pickering receives 28,000 stock options - Stock Titan
Director Romano Kelly receives 28,000 LeonaBio (LONA) stock options at $9.54 - Stock Titan
LeonaBio (LONA) director receives options to buy 28,000 shares at $9.54 - Stock Titan
LeonaBio (LONA) director awarded options on 28,000 shares at $9.54 - Stock Titan
LeonaBio (LONA) grants CMO 350,000 options at $9.54 - Stock Titan
Director John M. Fluke Jr. receives 28,000-share option grant at LeonaBio (LONA) - Stock Titan
LeonaBio (LONA) awards 300,000 stock options to general counsel - Stock Titan
LeonaBio (LONA) CFO awarded 300,000 stock options at $9.54 - Stock Titan
LeonaBio (LONA) CEO awarded 750,000 stock options at $9.54 strike - Stock Titan
Leonabio Inc Azioni (LONA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Leonabio Inc Azioni (LONA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Litton Mark James | PRESIDENT and CEO |
Mar 04 '26 |
Sale |
5.37 |
5,156 |
27,688 |
57,926 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
3,900 |
0 |
16,757 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
906 |
4,865 |
15,851 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 03 '26 |
Option Exercise |
0.00 |
5,726 |
0 |
19,704 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 04 '26 |
Sale |
5.37 |
1,328 |
7,131 |
18,376 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
5,856 |
0 |
26,537 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,359 |
7,298 |
25,178 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
7,418 |
0 |
17,607 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,720 |
9,236 |
15,887 |
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):